Mark Kowalski

3.6k total citations · 1 hit paper
50 papers, 2.8k citations indexed

About

Mark Kowalski is a scholar working on Genetics, Molecular Biology and Virology. According to data from OpenAlex, Mark Kowalski has authored 50 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 10 papers in Molecular Biology and 10 papers in Virology. Recurrent topics in Mark Kowalski's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers), HIV Research and Treatment (10 papers) and HIV/AIDS drug development and treatment (7 papers). Mark Kowalski is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers), HIV Research and Treatment (10 papers) and HIV/AIDS drug development and treatment (7 papers). Mark Kowalski collaborates with scholars based in United States, Canada and United Kingdom. Mark Kowalski's co-authors include Joseph Sodroski, William A. Haseltine, Tatyana Dorfman, C A Rosen, Andrew I. Dayton, Wei Chun Goh, Ernest F. Terwilliger, Bruce D. Walker, W A Haseltine and Udy Olshevsky and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Mark Kowalski

49 papers receiving 2.7k citations

Hit Papers

Functional Regions of the Envelope Glycoprotein of Human ... 1987 2026 2000 2013 1987 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Functional Regions of the Envelope Glycoprotein of Human Immunodeficiency Virus Type 1
    1987 764 citations Mark Kowalski, William A. Haseltine et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Kowalski United States 21 1.5k 991 876 829 361 50 2.8k
Éric Champagne France 27 1.5k 1.0× 1.3k 1.3× 807 0.9× 2.2k 2.7× 132 0.4× 60 4.5k
Abraham Karpas United Kingdom 32 650 0.4× 1.8k 1.8× 550 0.6× 1.1k 1.3× 383 1.1× 113 4.1k
F. Dianzani Italy 38 1.0k 0.7× 684 0.7× 901 1.0× 1.7k 2.1× 140 0.4× 187 4.2k
Xuejun Chen United States 22 498 0.3× 408 0.4× 260 0.3× 588 0.7× 235 0.7× 61 1.8k
Richard J. Gulizia United States 17 1.0k 0.7× 548 0.6× 500 0.6× 1.3k 1.6× 54 0.1× 22 2.5k
Jean‐Marie Andrieu France 28 1.2k 0.8× 449 0.5× 586 0.7× 953 1.1× 94 0.3× 89 2.8k
Naoki Oyaizu Japan 33 1.3k 0.9× 881 0.9× 464 0.5× 2.0k 2.4× 83 0.2× 106 3.3k
L Riddle United States 20 1.6k 1.0× 1.3k 1.3× 602 0.7× 820 1.0× 35 0.1× 26 3.2k
Richard Rudersdorf United States 25 813 0.5× 659 0.7× 344 0.4× 1.4k 1.7× 135 0.4× 32 2.7k
Geneviève Boucher Canada 22 1.5k 1.0× 982 1.0× 989 1.1× 1.1k 1.3× 139 0.4× 32 3.0k

Countries citing papers authored by Mark Kowalski

Since Specialization
Citations

This map shows the geographic impact of Mark Kowalski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Kowalski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Kowalski more than expected).

Fields of papers citing papers by Mark Kowalski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Kowalski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Kowalski. The network helps show where Mark Kowalski may publish in the future.

Co-authorship network of co-authors of Mark Kowalski

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Kowalski. A scholar is included among the top collaborators of Mark Kowalski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Kowalski. Mark Kowalski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Kristeleit, Rebecca, Ruth Plummer, Robert H. Jones, et al.. (2023). A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer. British Journal of Cancer. 129(1). 38–45. 22 indexed citations
4.
Adiibokah, Edward, et al.. (2023). Policymakers’ and healthcare providers’ perspectives on the introduction of oral pre-exposure prophylaxis for key populations in Ghana. BMC Public Health. 23(1). 1065–1065. 5 indexed citations
5.
Jones, Robert H., Ruth Plummer, Víctor Moreno, et al.. (2022). A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer. Clinical Cancer Research. 29(2). 331–340. 27 indexed citations
6.
Tun, Waimar, et al.. (2021). Perspectives of Policymakers on the Introduction and Scale-Up of HIV Self-Testing and Implication for National HIV Programming in Ghana. Frontiers in Public Health. 9. 694836–694836. 8 indexed citations
7.
Padda, Sukhmani K., Karen L. Reckamp, Marianna Koczywas, et al.. (2021). A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 89(1). 105–115. 12 indexed citations
8.
Mesa, Ruben A., Stephen T. Oh, Aaron T. Gerds, et al.. (2021). Association of transfusion independence with improved overall survival in myelofibrosis patients receiving momelotinib.. Journal of Clinical Oncology. 39(15_suppl). 7046–7046. 3 indexed citations
9.
Pardanani, Animesh, Rebecca R. Laborde, Terra L. Lasho, et al.. (2013). Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 27(6). 1322–1327. 173 indexed citations
10.
Pardanani, Animesh, Jason Gotlib, Vikas Gupta, et al.. (2012). Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis. Blood. 120(21). 178–178. 14 indexed citations
11.
Pardanani, Animesh, Jason Gotlib, Vikas Gupta, et al.. (2011). An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,. Blood. 118(21). 3849–3849. 26 indexed citations
12.
Pardanani, Animesh, T L Lasho, WJ Hogan, et al.. (2011). Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis.. Journal of Clinical Oncology. 29(15_suppl). 6514–6514. 23 indexed citations
13.
Kowalski, Mark, et al.. (2010). A Pharmacokinetic Analysis of Diclofenac Potassium Soft-Gelatin Capsule in Patients After Bunionectomy. American Journal of Therapeutics. 17(5). 460–468. 7 indexed citations
14.
15.
Stiff, Dwight D., et al.. (2009). Single-dose pharmacokinetic study of rapidly dispersing diclofenac potassium formulations in healthy volunteers. Current Medical Research and Opinion. 25(10). 2423–2428. 10 indexed citations
16.
17.
Marshall, William L., David C. Diamond, Mark Kowalski, & Robert W. Finberg. (1992). High level of surface CD4 prevents stable human immunodeficiency virus infection of T-cell transfectants. Journal of Virology. 66(9). 5492–5499. 27 indexed citations
18.
Sodroski, Joseph, William A. Haseltine, & Mark Kowalski. (1991). Role of the Human Immunodeficiency Virus Type I Envelope Glycoprotein in Cytopathic Effect. Advances in experimental medicine and biology. 300. 193–201. 4 indexed citations
19.
Kowalski, Mark, et al.. (1988). Cis-acting sequences responsive to the rev gene product of the human immunodeficiency virus.. PubMed. 1(5). 441–52. 67 indexed citations
20.
Kowalski, Mark, et al.. (1979). Partial purification of Rho (D) antigen from Rh positive and negative erythrocytes.. Proceedings of the National Academy of Sciences. 76(6). 2964–2968. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Éric Champagne Breakdown of academic impact, for papers by Abraham Karpas Breakdown of academic impact, for papers by F. Dianzani Breakdown of academic impact, for papers by Xuejun Chen Breakdown of academic impact, for papers by Richard J. Gulizia Breakdown of academic impact, for papers by Jean‐Marie Andrieu Breakdown of academic impact, for papers by Naoki Oyaizu Breakdown of academic impact, for papers by L Riddle Breakdown of academic impact, for papers by Richard Rudersdorf Breakdown of academic impact, for papers by Geneviève Boucher
Rankless by CCL
2026